Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Therapeutics LlcfiledCriticalCompass Therapeutics Llc
Publication of AR112758A1publicationCriticalpatent/AR112758A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente se refiere, a compuestos (por ej., anticuerpos, o fragmentos de unión al antígeno de los mismos) que se unen a un epítopo de CD137 y agonizan CD137, y al uso de compuestos en métodos para tratar cáncer o aliviar uno o más de sus síntomas. Composición farmacéutica; ácido nucleico; vector; célula; kit.This relates to compounds (eg, antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to the use of compounds in methods of treating cancer or alleviating one or more more of your symptoms. Pharmaceutical composition; nucleic acid; vector; cell; kit.
ARP180101930A2017-07-112018-07-11
AGONIST ANTIBODIES BINDING HUMAN CD137, AND USES OF THE SAME
AR112758A1
(en)
antibody, nucleic acid construct, expression vector, host cell, composition, methods for treating a disease, producing a bispecific antibody, and detecting the possible occurrence of crosslinking between cd3 and cd20-expressing cells in a derived sample of a patient, use of a bispecific antibody, and kit?